Alnylam Pharmaceuticals Inc. (ALNY) exhibits 81.8% gross margins and 21.3% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 42.4x enterprise multiple and 6.9% implied options volatility.
Sustained 81.8% gross profitability converts into 13.5% operating margin and 21.3% ROIC, outpacing sector cost of capital.
ROIC: 21.3% // GM: 81.8%YoY revenue trajectory of +65.2% paired with 2.00% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +65.2% // FCF YLD: 2.00%Altman Z-Score of 3.16 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.16 // F-SCORE: 8/9Trading at 74.2x trailing P/E (62.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 74.2x // EV/EBITDA: 42.4xOptions market prices a ±6.9% implied move with a 1.65 put/call ratio around $171.00 max pain.
IMPL MOVE: ±6.9% // P/C: 1.65Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.4% net margins.
NET MARGIN: 8.4% // D/E: 2.22x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ALNY & activate live FRED threshold breach alerts.